Tg Therapeutics (TGTX) Short-term Investments (2014 - 2026)

Tg Therapeutics' Short-term Investments history runs 13 years deep, the most recent figure standing at $72.2 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 49.88% year-over-year to $72.2 million; the TTM figure through Mar 2026 stood at $72.2 million (down 49.88% YoY), while the FY2025 annual figure was $62.8 million, down 52.08% from the prior year.
• Short-term Investments for Q1 2026 stood at $72.2 million, up from $62.8 million in the prior quarter.
• The five-year high for Short-term Investments was $145.2 million in Q3 2024, with the low at $47.5 million in Q1 2022.
• The 5-year median for Short-term Investments is $78.2 million (2023), against an average of $91.5 million.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments soared 273.99% in 2022, then slumped 60.4% in 2025.
• Tg Therapeutics' Short-term Investments stood at $59.4 million in 2022, then surged by 109.81% to $124.6 million in 2023, then increased by 5.24% to $131.1 million in 2024, then sank by 52.08% to $62.8 million in 2025, then advanced by 14.96% to $72.2 million in 2026.
• Business Quant data shows TGTX's Short-term Investments at $72.2 million in Q1 2026, $62.8 million in Q4 2025, and $57.5 million in Q3 2025.